Dr. Huntington Potter at the University of Colorado Anschutz Medical Center has shown that GM-CSF (recombinant human Granulocyte-Macrophage Colony-Stimulating Factor such as the commercially available Leukine) can slow or reverse Alzheimer’s disease (AD) (CU#4306H). However, continuous treatment of AD patients with Leukine would be expensive at its current cost (>$200,000/year/patient) and it would be difficult to produce sufficient quantities. To counter these difficulties, Dr. Potter has developed new GM-CSF peptides that act as GM-CSF mimetics. The mimetics are smaller in size and easier to synthesize than GM-CSF itself. They also show improved bioavailability, improved stability, easier administration, improved blood brain barrier permeability, and improved oral bioavailability.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/market_summary_cu4121h.pdf